Press Releases

NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Currently, there are over 1.5 million nonprofits registered in the U.S., including the nation's largest suicide prevention organization, the

PRINCETON, N.J., Nov. 6, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Daniel P. Ring, Vice President of Business Development and S

TARRYTOWN, N.Y. and ROCHESTER, Minn., Nov. 6, 2019 /PRNewswire/ -- Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration will explore new oncolytic virus treatmentsVyriad to receive upfront payment and e

SÃO JOSÉ DO RIO PRETO, Brazil and Greenwich, Conn., Nov. 6, 2019 /PRNewswire/ -- OdontoCompany (the "Company"), a leading and growth-oriented dental clinic franchisor in Brazil, today announced that it has received a significant strategic investment from the Latin America fund of

BOSTON, Nov. 6, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced completion of enrollment in the Company's global, multicenter, randomized, placebo-controlled, 28-day, Phase 2 study evalua

WALTHAM, Mass., Nov. 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the first patient has been dosed in AUGMENT-101, a Phase 1/2 clinical trial evaluating SNDX-5613, Syndax's potent, highly sel

SMITHS FALLS, ON, Nov. 5, 2019 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NYSE: CGC) will release its financial results for the second quarter fiscal 2020 ended September 30, 2019 before financial markets open on November 14, 2019.

TEL AVIV, Israel, Nov. 6, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended September 30, 2019 on Monday, November 11, 2019, before the US mark

TEL AVIV, Israel, Nov. 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral SCD1 modulator currently in a Phase 3/4 clinical trial for the treatment of nonalcoholic steatohepatitis ("NASH") and fibrosis provides today a busi

KFAR SABA, Israel, Nov. 6, 2019 /PRNewswire/ -- Following the AnapnoGuard™ airway management system's FDA market clearance at the end of 2018, Hospitech Respiration announced that a new article was recently published by physicians from